Verastem, Inc. Share Price & Technical Analysis
VSTM · $4.24 (-0.70%)
Healthcare / Biotechnology
$4.24
-0.70%
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-22% return in May, 31% avg return in past 3 year May month.
-53% return in 2026, 90% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -21% | -7% | -5% | 2% | -22% | – | – | – | – | – | – | – | -53% |
| 25 | 20% | -3% | 5% | 25% | 0% | -45% | 48% | 53% | -2% | 7% | 13% | -26% | 94% |
| 24 | 46% | 7% | -7% | -16% | -60% | -25% | -13% | -4% | 20% | 27% | 39% | -4% | 10% |
| 23 | 66% | -19% | -19% | -6% | 154% | -38% | 50% | -12% | -17% | -22% | 10% | 19% | 165% |
| 22 | -25% | -23% | 17% | 1% | -10% | -11% | -7% | 9% | -27% | -53% | 6% | -13% | -136% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$417.52M
P/E ratio
—
52W high
$11.25
52W low
$4.00
Volume
16,08,366
Beta
0.34
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Verastem, Inc. share price today?
- Verastem, Inc. (VSTM) last traded around $4.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VSTM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VSTM. Download the app for real-time alerts.
- How can I analyze Verastem, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.